Spandidos出版社期刊
期刊
会议
图书
作者:Yangyang Zhang , Xianting Ke , Jingjing Liu ...
来源:[J].Molecular Medicine Reports(IF 1.17), 2019, Vol.19 (1), pp.638-650Spandidos
摘要:Circular RNAs (circRNAs) are non-coding RNAs forming closed-loop structures,and their aberrant expression may lead to disease. However, the potential networkof circRNA‑associated competing endogenous RNA (ceRNA) involved in nonvalvularpersistent atrial fibrillation (NPAF) ha...
作者:Chao Ci , Biao Tang , Dalun Lyu ...
来源:[J].International Journal of Molecular Medicine(IF 1.957), 2019, Vol.43 (1), pp.404-412Spandidos
摘要:Cutaneous melanoma is very aggressive and results in high mortality ratesfor cancer patients. Determining molecular targets is important for developingnovel therapies for cutaneous melanoma. Cell division cycle associated 8 (CDCA8)is a putative oncogene that is upregulated i...
作者:Hua Li , Xiaofen Meng , Di Zhang ...
来源:[J].Oncology Reports(IF 2.297), 2019, Vol.41 (1), pp.369-376Spandidos
摘要:Liver cancer is one of the most devastating types of cancer worldwide. Despiteyears of improvements in treatment, the prognosis of patients with this type ofmalignancy remains poor due to frequent recurrence and metastasis after surgicalresection. Ginkgolic acid (GA) is a bo...
作者:Ye Liu , Saiyue Gao , Qingyan Du ...
来源:[J].International Journal of Molecular Medicine(IF 1.957), 2019, Vol.43 (1), pp.547-556Spandidos
摘要:Long non‑coding RNA (lncRNA) metastasis associated lung adenocarcinoma transcript1 (MALAT1) has been demonstrated to participate in the development and progressionof some common cancer types, including bladder cancer (BC). However, the regulatorymechanism of MALAT1 underlyin...
作者:Xiaobin Wang , Huihan Wang , Yongsheng Song
来源:[J].Oncology Letters(IF 0.237), 2019, Vol.17 (1), pp.201-208Spandidos
摘要:The clinical efficacy and mechanism of Pralatrexate (PTX) combined withPalbociclib Isethionate (PAL) in the treatment of bladder cancer patients wasinvestigated. A retrospective analysis of medical records of 82 bladder cancerpatients admitted to Shengjing Hospital of China Medic...
作者:Lijuan Dai , Gaofeng Shi , Yang Li ...
来源:[J].Oncology Letters(IF 0.237), 2019, Vol.17 (1), pp.355-359Spandidos
摘要:This study aimed to evaluate the values of thoracic multi‑slice spiral computedtomography (CT) in the diagnosis of incidental pulmonary thromboembolism (IPTE)in patients with malignant tumors. The clinical data and imaging features of atotal of 1,684 patients with malignant ...
作者:Zhangwei Hu , Lei Wang , Yong Han ...
来源:[J].Oncology Letters(IF 0.237), 2019, Vol.17 (1), pp.314-322Spandidos
摘要:Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancerin the world, yet current treatment options are associated with limited success.The aim of the present study was to investigate the expression of ferritin inHNSCC and clarify whether it may serve as a bi...
作者:Lukuan You , Jinliang Wang , Fan Zhang ...
来源:[J].Molecular Medicine Reports(IF 1.17), 2019, Vol.19 (1), pp.441-451Spandidos
摘要:With a 5‑year survival rate of only 8%, pancreatic ductal adenocarcinoma(PDAC) is the fourth leading cause of cancer‑associated mortality worldwide. Unfortunately,even following radical surgery, patient outcomes remain poor. Emerging as a newclass of biomarkers in human canc...
作者:Miwako Omori , Yusuke Okuma , Taiki Hakozaki ...
来源:[J].Molecular and Clinical Oncology, 2019, Vol.10 (1), pp.137-143Spandidos
摘要:There are a number of suggested predictive factors of nivolumab for non‑smallcell lung cancer (NSCLC), however, there is not enough evidence to determine asingle factor that can predict the efficacy of nivolumab. As the progress of biomarkersfor cancer treatment is improving...
作者:Baohua Li , Shu Zhang , Na Huang ...
来源:[J].Oncology Reports(IF 2.297), 2019, Vol.41 (1), pp.608-618Spandidos
摘要:Myeloid‑derived suppressor cells (MDSCs) are the major negative regulatorsof immune responses and expand in numerous tumor models. They contribute to tumorprogression and metastasis, and are involved in limiting the effects of cancerimmunotherapy. To selectively target MDSCs...

我们正在为您处理中,这可能需要一些时间,请稍等。

资源合作:cnki.scholar@cnki.net, +86-10-82896619   意见反馈:scholar@cnki.net

×